BioMarin is currently seeking patients for a Phase 3 clinical trial in Late Onset Pompe Disease.
This phase 3 study incorporates a switchover design in which all patients switch
directly from Myozyme® or Lumizyme®* to the experimental drug BMN 701 without
missing doses, to determine if patients currently on enzyme replacement therapy
with Myozyme® or Lumizyme® can improve more in measures of respiratory
muscle strength, muscle weakness and endurance.
Patients will not be required to spend their own money for study related travel.
The trial related travel costs, including hotels, car rentals/taxis, airfare/train fare,
mileage, food and any other approved trial related expenses will be paid by
BioMarin. Arrangements will also be made for special travel needs, such as
wheelchair accessible taxis and hotel rooms as well as transportation through the
*Myozyme and Lumizyme are registered trademarks of Genzyme, a Sanofi Company